Cargando…
Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays
Several studies have reported serological cross-reactivity of the immune responses between SARS-CoV-2 and DENV. Most of the available studies are based on the point-of-care rapid testing kits. However, some rapid test kits have low specificity and can generate false positives. Hence, we aimed to inv...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059058/ https://www.ncbi.nlm.nih.gov/pubmed/35134813 http://dx.doi.org/10.1159/000522479 |
_version_ | 1784698235286192128 |
---|---|
author | Shurrab, Farah M. Al-Sadeq, Duaa W. Amanullah, Fatima Humaira Al-Absi, Enas S. Qotba, Hamda Yassine, Hadi M. Abu-Raddad, Laith J. Nasrallah, Gheyath K. |
author_facet | Shurrab, Farah M. Al-Sadeq, Duaa W. Amanullah, Fatima Humaira Al-Absi, Enas S. Qotba, Hamda Yassine, Hadi M. Abu-Raddad, Laith J. Nasrallah, Gheyath K. |
author_sort | Shurrab, Farah M. |
collection | PubMed |
description | Several studies have reported serological cross-reactivity of the immune responses between SARS-CoV-2 and DENV. Most of the available studies are based on the point-of-care rapid testing kits. However, some rapid test kits have low specificity and can generate false positives. Hence, we aimed to investigate the potential serological cross-reactivity between SARS-CoV-2 and DENV-IgG antibodies using advanced assays including chemiluminescence immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA) test. A total of 90 DENV-IgG-ELISA-positive and 90 DENV-IgG-ELISA-negative prepandemic sera were tested for anti-SARS-CoV-2-IgG using the automated CL-900i CLIA assay. Furthermore, a total of 91 SARS-CoV-2-IgG-CLIA-positive and 91 SARS-CoV-2-IgG-CLIA-negative postpandemic sera were tested for anti-DENV-IgG using the NovaLisa ELISA kit. The DENV-IgG-positive sera resulted in five positives and 85 negatives for SARS-CoV-2-IgG. Similarly, the DENV-IgG-negative sera also resulted in 5 positives and 85 negatives for SARS-CoV-2-IgG. No statistically significant difference in specificity between the DENV-IgG-positive and DENV-IgG-negative sera was found (p value = 1.00). The SARS-CoV-2-IgG-positive sera displayed 43 positives, 47 negatives, and 1 equivocal for DENV-IgG, whereas the SARS-CoV-2-IgG-negative sera resulted in 50 positives, 40 negatives, and 1 equivocal for DENV-IgG. No statistically significant difference in the proportion that is DENV-IgG positive between the SARS-CoV-2-IgG-positive and SARS-CoV-2-IgG-negative sera (p value = 0.58). In conclusion, there is a low risk of serological cross-reactivity between the DENV and SARS-CoV-2-IgG antibodies when using advanced detection assays. |
format | Online Article Text |
id | pubmed-9059058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-90590582022-05-03 Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays Shurrab, Farah M. Al-Sadeq, Duaa W. Amanullah, Fatima Humaira Al-Absi, Enas S. Qotba, Hamda Yassine, Hadi M. Abu-Raddad, Laith J. Nasrallah, Gheyath K. Intervirology Brief Report Several studies have reported serological cross-reactivity of the immune responses between SARS-CoV-2 and DENV. Most of the available studies are based on the point-of-care rapid testing kits. However, some rapid test kits have low specificity and can generate false positives. Hence, we aimed to investigate the potential serological cross-reactivity between SARS-CoV-2 and DENV-IgG antibodies using advanced assays including chemiluminescence immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA) test. A total of 90 DENV-IgG-ELISA-positive and 90 DENV-IgG-ELISA-negative prepandemic sera were tested for anti-SARS-CoV-2-IgG using the automated CL-900i CLIA assay. Furthermore, a total of 91 SARS-CoV-2-IgG-CLIA-positive and 91 SARS-CoV-2-IgG-CLIA-negative postpandemic sera were tested for anti-DENV-IgG using the NovaLisa ELISA kit. The DENV-IgG-positive sera resulted in five positives and 85 negatives for SARS-CoV-2-IgG. Similarly, the DENV-IgG-negative sera also resulted in 5 positives and 85 negatives for SARS-CoV-2-IgG. No statistically significant difference in specificity between the DENV-IgG-positive and DENV-IgG-negative sera was found (p value = 1.00). The SARS-CoV-2-IgG-positive sera displayed 43 positives, 47 negatives, and 1 equivocal for DENV-IgG, whereas the SARS-CoV-2-IgG-negative sera resulted in 50 positives, 40 negatives, and 1 equivocal for DENV-IgG. No statistically significant difference in the proportion that is DENV-IgG positive between the SARS-CoV-2-IgG-positive and SARS-CoV-2-IgG-negative sera (p value = 0.58). In conclusion, there is a low risk of serological cross-reactivity between the DENV and SARS-CoV-2-IgG antibodies when using advanced detection assays. S. Karger AG 2022-02-08 /pmc/articles/PMC9059058/ /pubmed/35134813 http://dx.doi.org/10.1159/000522479 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Brief Report Shurrab, Farah M. Al-Sadeq, Duaa W. Amanullah, Fatima Humaira Al-Absi, Enas S. Qotba, Hamda Yassine, Hadi M. Abu-Raddad, Laith J. Nasrallah, Gheyath K. Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays |
title | Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays |
title_full | Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays |
title_fullStr | Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays |
title_full_unstemmed | Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays |
title_short | Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays |
title_sort | low risk of serological cross-reactivity between the dengue virus and sars-cov-2-igg antibodies using advanced detection assays |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059058/ https://www.ncbi.nlm.nih.gov/pubmed/35134813 http://dx.doi.org/10.1159/000522479 |
work_keys_str_mv | AT shurrabfarahm lowriskofserologicalcrossreactivitybetweenthedenguevirusandsarscov2iggantibodiesusingadvanceddetectionassays AT alsadeqduaaw lowriskofserologicalcrossreactivitybetweenthedenguevirusandsarscov2iggantibodiesusingadvanceddetectionassays AT amanullahfatimahumaira lowriskofserologicalcrossreactivitybetweenthedenguevirusandsarscov2iggantibodiesusingadvanceddetectionassays AT alabsienass lowriskofserologicalcrossreactivitybetweenthedenguevirusandsarscov2iggantibodiesusingadvanceddetectionassays AT qotbahamda lowriskofserologicalcrossreactivitybetweenthedenguevirusandsarscov2iggantibodiesusingadvanceddetectionassays AT yassinehadim lowriskofserologicalcrossreactivitybetweenthedenguevirusandsarscov2iggantibodiesusingadvanceddetectionassays AT aburaddadlaithj lowriskofserologicalcrossreactivitybetweenthedenguevirusandsarscov2iggantibodiesusingadvanceddetectionassays AT nasrallahgheyathk lowriskofserologicalcrossreactivitybetweenthedenguevirusandsarscov2iggantibodiesusingadvanceddetectionassays |